VenoStent, Inc.

VenoStent is a venture backed, clinical stage medical device and tissue engineering company developing bioabsorbable wraps to transform outcomes in vascular surgery

http://www.venostent.com

11-50 employees

Growth Trajectory

VenoStent is poised for growth through the successful completion of its SAVE-FistulaS clinical trial and subsequent FDA approval of SelfWrap. Market expansion could occur through applications in coronary and peripheral bypass grafting, as well as collaborations with dialysis centers and vascular surgeons. The company's focus on bioabsorbable materials and 3D printing provides a strong foundation for further innovation and product development.

Technical Challenges

Ensuring the bioabsorbable material provides adequate mechanical support and promotes desired vein growth.

Optimizing the biomimetic mechanical support and bioabsorption characteristics of SelfWrap.

Scaling manufacturing for clinical and commercial supply of SelfWrap.

Meeting regulatory requirements for medical devices.

Tech Stack

Bioabsorbable materialsMedical 3D printingTissue engineeringShape memory polymers

Team Size

Key Risks

Clinical trials may not demonstrate statistically significant improvements in AV access site outcomes compared to existing treatments.

Regulatory approval from the FDA is not guaranteed and may be delayed due to unforeseen challenges.

Competitors may develop alternative solutions that prove more effective or cost-efficient.

Scaling manufacturing of SelfWrap may present unforeseen technical or logistical challenges.

Adoption by vascular surgeons may be slower than anticipated due to lack of familiarity with the technology or concerns about integration with existing procedures.

Opportunities

Successful clinical trial results could lead to rapid adoption of SelfWrap as the standard of care for AV access site creation.

Expansion into coronary and peripheral bypass grafting applications could significantly broaden the market for SelfWrap.

Strategic partnerships with dialysis centers and vascular surgeons could streamline the adoption and use of SelfWrap.

Further refinement of bioabsorbable materials and 3D printing techniques could lead to new and improved vascular support devices.

Positive outcomes with SelfWrap could enhance the company's reputation and attract further investment.

Live Data Stream

Access Our Live VC Funding Database

30,000+ funded startups

tracked in the last 3 months

B2B verified emails

of key decision makers

Growth metrics

Real-time company performance data

Live updates

of new VC funding rounds

Advanced filters

for sophisticated queries

API access

with multiple export formats

Access Database

Updated every 5 minutes